Emphasis on pleiotropic effects, a new paradigm shift?

Coron Artery Dis. 2004 Aug;15(5):223-5. doi: 10.1097/01.mca.0000131571.06897.da.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology*
  • Anticholesteremic Agents / therapeutic use
  • Cholesterol, HDL / drug effects
  • Cholesterol, LDL / drug effects
  • Clinical Trials as Topic
  • Coronary Artery Disease / prevention & control
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use

Substances

  • Anticholesteremic Agents
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors